

# TAKAFULINK DANA ESG GLOBAL

All information as at 30 April 2024 unless otherwise stated


Semua maklumat adalah seperti pada 30 April 2024 melainkan jika dinyatakan

## Objective / Objektif Dana

Takafulink Dana ESG Global (The Fund) aims to maximise returns over long term by investing in a qualified Sustainable and Responsible Investment (SRI) Fund.

Takafulink Dana ESG Global (Dana) bertujuan memaksimumkan pulangan jangka masa panjang dengan melabur dalam Dana Pelaburan Mampan dan Bertanggungjawab (SRI) yang layak.

## Where the Fund invests Komposisi Pelaburan Dana



### Asset Allocation Peruntukan Aset

	% NAV
1 Nomura Global Shariah Sustainable Equity Fund	101.12
2 Cash, Deposits & Others	-1.12

## Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan Prudential BSN Takaful Berhad

Inception Date / Tarikh Diterbitkan 20/03/2023


Current Fund Size / Saiz Dana Terkini RM2,839,743.52

Annual Fund Management Charge / Caj Pengurusan Dana Tahunan 1.50% per annum

Current NAV / NAB Terkini RM1.25572

## How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana  
Takafulink Dana ESG Global Vs. Dow Jones Islamic Market  
Developed Markets Index



### Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	-0.45%	6.49%	20.99%	25.57%	NA	NA	25.57%
Benchmark / Penanda Aras	-3.28%	4.57%	21.26%	0.00%	NA	NA	29.40%
Outperformance / Perbezaan Prestasi	2.83%	1.92%	-0.27%	25.57%	NA	NA	-3.83%

# TAKAFULINK DANA ESG GLOBAL

All information as at 30 April 2024 unless otherwise stated

Semua maklumat adalah seperti pada 30 April 2024 melainkan jika dinyatakan

## Monthly Update / Laporan Bulanan Terkini

### Fund Review & Strategy

The Fund returned -0.45% for the month, outperforming the benchmark return of -3.28% by 2.83%. Year-to-date, The Fund returned 12.54%, outperforming the benchmark return of 8.87% by 3.67%. Global equity market YTD rally took a pause as US inflation data remains sticky which Fed fund futures now implied 1-2 rate cuts by 2024 from previous 3-4 rate cuts. There were even market narratives about rate hike which the Target Fund Manager does not believe and Fed Chairman Jerome Powell has denied on the Fed meeting as well. In addition, the earnings announcement from ASML and TSMC without marginal positive surprises in their guidance disappointed the market despite decent earnings beats. The Target Fund Manager thinks that such expectation reset is healthy for a sustainable performance and would continue to take advantage of this pullback opportunity for the long-term. The Target Fund strategy managed to perform better when market was down mainly attributed to positive selections and strong earnings from their investment holdings. By region, all regions contributed positively to the outperformance with North America as the top contributor followed by Western Europe even though Western Europe is the least decliner. Strong selections help offset the negative allocation within North America. By sector, Healthcare and Industrials were the top contributors. There was offset from underweight in sectors with positive monthly performance such as Energy and Utilities. The top contributors to relative performance were Astrazeneca PLC and Tetra Tech. Both companies delivered earnings beat and raised guidance. On the other hand, the top detractors to relative performance were Gilead and Abbvie. Gilead delivered earnings beat but market didn't receive well Tredelvy, one of the oncology drugs, data. Abbvie delivered slight misses on earnings but more importantly the Target Fund Manager think market overreacted to the cadence of Humira rolling off from its patent expiration in 2023 and underappreciated the growth potential of Skyrizi and Rinvoq, which both drugs are to treat different types of arthritis.

### Tinjauan & Strategi Dana

Dana menjana pulangan -0.45% pada bulan ini, mengatasi pulangan penanda aras -3.28% dengan perbezaan 2.83%. Sejak awal tahun sehingga bulan tinjauan, Dana memperoleh pulangan 12.54%, mengatasi pulangan penanda aras 8.87% dengan kelebihan 3.67%. Kenaikan pasaran ekuiti global YTD berhenti seketika kerana data inflasi US kekal melekit yang mana niaga hadapan dana Fed kini membayangkan 1-2 pemotongan kadar faedah menjelang 2024 berbanding pemotongan sebelumnya. Malah, terdapat naratif pasaran mengenai kenaikan kadar yang tidak meyakinkan Pengurus Dana Sasaran sementara Pengerusi Fed Jerome Powell juga telah menafikan hal tersebut semasa mesyuarat Fed. Di samping itu, pengumuman pendapatan ASML dan TSMC tidak diiringi kejutan positif kecil dalam panduannya mengecewakan pasaran walaupun rentak pendapatan lumayan. Pengurus Dana Sasaran berpendapat bahawa penetapan semula jangkaan tersebut sihat untuk prestasi yang mampan dan akan terus memanfaatkan peluang pengunduran buat jangka panjang. Strategi Dana Sasaran berjaya menunjukkan prestasi yang lebih baik apabila pasaran turun terutamanya disebabkan oleh pemilihan positif dan pendapatan kukuh lantaran pegangan pelaburan. Mengikut rantau, semua rantau menyumbang secara positif kepada prestasi baik dengan Amerika Utara sebagai penyumbang utama diikuti oleh Eropah Barat walaupun Eropah Barat merosot paling sedikit. Pilihan yang kukuh membantu mengimbangi peruntukan negatif dalam Amerika Utara. Menurut sektor, Penjagaan Kesihatan dan Perindustrian merupakan penyumbang utama. Kekurangan pegangan dalam sebahagian sektor ditimbang dengan prestasi bulanan positif seperti Tenaga dan Utiliti. Penyumbang utama kepada prestasi relatif ialah Astrazeneca PLC dan Tetra Tech. Kedua-dua syarikat menyampaikan pendapatan yang rancak dan menaikkan panduan. Sebaliknya, penjejas prestasi relatif yang paling besar ialah Gilead dan Abbvie. Gilead menyampaikan rentak pendapatan tetapi pasaran tidak menerima data Tredelvy, salah satu ubat onkologi. Abbvie mencatat pendapatan yang sedikit terlepas tetapi yang lebih penting ialah Pengurus Dana Sasaran berpendapat bahawa pasaran bertindak keterlaluan terhadap irama Humira yang bermula daripada tamat tempoh patennya pada tahun 2023 dan potensi pertumbuhan Skyrizi dan Rinvoq dipandang rendah, yang mana kedua-dua ubat itu merupakan rawatan kepada pelbagai jenis artritis.

Source / Sumber: Fund Commentary, April 2024, Nomura Asset Management Malaysia Sdn. Bhd.

### Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL